Platelet aggregation inhibitor

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Drugs that inhibit platelet aggregation by inhibiting prostaglandin synthesis and are thus used for thrombosis prophylaxis. The most important thrombocyte aggregation inhibitors are acetylsalicylic acid, ticlopidine and clopidogrel. The use of sulfinpyrazone is largely abandoned.

IndicationThis section has been translated automatically.

Among other things, in the case of a heart attack, apoplexy, arterial occlusive disease.

Authors

Last updated on: 29.10.2020